Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biosimilars Forum Urges Equal Access For US Humira Rivals

Executive Director Julie Reed Calls For Availability As Adalimumab Biosimilars Launch

Executive Summary

With the US on the cusp of biosimilar competition to Humira, Julie Reed – executive director of the country’s Biosimilars Forum – has urged PBMs to bolster access by making all adalimumab biosimilars available as they launch throughout 2023.

You may also be interested in...



Optum Rx Reveals Humira Biosimilar Plan To ‘Support Advancement Of The Market’

United Health's pharmacy benefit manager outlined plans for early inclusion of up to three biosimilar versions of adalimumab on its formularies in 2023, at parity to the brand.

Organon Believes It Can Beat Out Other Humira Rivals In US

As the biosimilars industry awaits several US adalimumab launches in 2023, Organon has set out the reasons why it believes it can stand out from its competitors.

Reed Sets Out Priorities For US Biosimilars Forum

In an exclusive interview with Generics Bulletin, the Biosimilars Forum’s executive director Julie Reed sets out the group’s priorities and explains how its diverse membership is helping to position it as a leading voice for the US biosimilars industry.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152451

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel